Enobosarm - GTx

Drug Profile

Enobosarm - GTx

Alternative Names: GTx-024; MK-2866; Ostarine; S-22

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GTx
  • Developer City of Hope National Medical Center; GTx; National Cancer Institute (USA)
  • Class Antineoplastics; Nitriles; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cachexia

Highest Development Phases

  • Phase II Breast cancer; Stress incontinence
  • Preclinical Duchenne muscular dystrophy
  • Discontinued Cachexia; Muscular atrophy

Most Recent Events

  • 21 Sep 2018 GTx terminates phase II trial in Stress incontinence in USA, due to lack of efficacy (NCT03508648)
  • 21 Sep 2018 GTx completes the phase II ASTRID trial for Stress incontinence in USA (NCT03241342)
  • 21 Sep 2018 Efficacy and adverse events data from the phase II ASTRID trial in Stress urinary incontinence (SUI) (in post-menopausal women) released by GTx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top